DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Ultra-high purity surfactant for biologics and parenteral drug formulations
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
The facility has been classified as Voluntary Action Indicated
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Importantly, the combination of giredestrant and everolimus was well tolerated
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Subscribe To Our Newsletter & Stay Updated